Transarterial Chemoembolization Combined With Donafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study
June 2024
in “
Journal of Clinical Oncology
”
Studysummary In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study evaluated the efficacy and safety of combining transarterial chemoembolization (TACE) with Donafenib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) in 48 patients. The median progression-free survival (PFS) was 12.8 months, and the one-year overall survival (OS) rate was 87.5%. The objective response rate was 58.3%, with a disease control rate of 81.3%. Common treatment-related adverse events included elevated AST (75.0%), increased bilirubin (72.9%), and elevated ALT (54.2%). Grade 3 or 4 adverse events were observed in 46.9% of patients, but no Grade 5 events occurred. The combination therapy showed good efficacy and tolerability, suggesting its potential as a first-line treatment for Chinese uHCC patients.
